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Abstract eptifibatide is an antiplatelet drug of the glycoprotein IIb/IIIa 
inhibitor class. Pharmaceutically it is applied to reduce the risk of acute 
cardiac ischemic events. The present work reveals two simple, rapid and 
economical uV-Spectrophotometric methods for pharmaceutical analysis of 
eptifibatide bulk and in parenteral formulation. The ‘Method I’ is based on the 
Zero Order uV-Spectrophotometric determination of drug at its wavelength 
maximum 218.20 nm and ‘Method II’ employed First Order Derivative - 
area under Curve (auC) technique in which the area has been integrated 
between two wavelengths 220.20 to 237.20 nm. The drug obeyed linearity in 
the concentration range of 3 - 18 µg/ml with coefficient of correlation; greater 
than 0.999 in both methods. The amounts of drug determined by both methods 
are in conformity with label claim. These methods are validated for accuracy, 
precision and ruggedness with % RSD value less than 2.0. 
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1. IntRodUctIon
eptifibatide is a cyclic heptapeptide antiplatelet drug of the glycoprotein IIb/
IIIa inhibitor class derived from protein found in the venom of the southeastern 
pygmy rattlesnake katori, N. et al. (2004). It is used in myocardial infarction and 
acute coronary syndrome hantgan, R. et al. (2001). Chemically eptifibatide is N6-
(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-l-lysylglycyl-l-α-aspartyl-
l-tryptophyl-l-prolyl-l-cysteinamide, cyclic (1→6) disulfide, The Merck Index 





literature revealed very few analytical methods such as hPlC kachhadia, 
P. (2008) and lC-Tandem Mass Spectroscopy liu, Z. et al. (2009), Yu, X. et 
al. (2010) for determination of eptifibatide in bulk, pharmaceutical formulation 
and in human plasma. To our knowledge there is no method for determination of 
eptifibatide by uV-Spectrophotometry in bulk and pharmaceutical formulations.
So, the objective of the present investigation was to develop simple, rapid, 
economical precise and accurate Zero order uV - Spectrophotometric and 
uV - Spectrophotometric - First Order Derivative- area under Curve (auC) 
methods for determination of eptifibatide in bulk and in parenteral formulation. 
The methods thus developed were also subjected to analytical validation as 
directed by the ICh guidelines (2005).
2. ExPERIMEntAl
2.1 Materials and Equipments
eptifibatide was obtained as a generous gift sample. Parenteral formulation 
was purchased from market, containing 20 mg vial (Integrilin). Spectroscopic 
measurement study was done using uV-Visible Spectrophotometer with 
software uV Probe 2.21 and spectral bandwidth 1 nm was employed for all 
samples, using a pair of 10 mm matched quartz cells. eptifibatide is soluble in 
distilled water therefore it was selected as a solvent.









2.2 Preparation of stock standard solution 
Stock standard solution was prepared by dissolving 10 mg of anhydrous 
eptifibatide in 100 ml of distilled water to obtain concentration of 100 µg/ml. 
2.3 Selection of analytical wavelengths and study of linearity curves
From the stock standard solution, an appropriate volume 1 ml was further 
diluted with distilled water to get concentration 10 µg/ml, scanned in the 
uV- region of 400 − 200 nm. eptifibatide showed maximum absorbance at 
wavelength 218.20 nm which was chosen for further studies in Method-I 
as shown in Fig. 2. The aforesaid spectrum was derivatized into first order 
derivative at delta lambda 2.0, scaling factor 4.0 using uV Probe 2.21 software 
and the auC was determined in the wavelength range of 220.20 nm -237.20 
nm in Method-II as depicted in Fig. 3. 
2.4 Preparation of Eptifibatide sample solution and assay
The sample vial containing 20 mg eptifibatide having concentration 2 mg/
ml; an appropriate portion of 5.0 ml was transferred into 100 ml volumetric 
flask containing 50 ml distilled water and diluted up to the mark with same. 
The resulting solution was filtered through Whatmann filter paper 0.45 µm. 
From it, an appropriate volume 0.9 ml was transferred into 10 ml volumetric 






flask and volume was made up with solvent. In Method-I, the absorbance was 
studied at the selected wavelength whereas in Method –II, the same spectrum 
was derivatized into first order and area under curve was recorded between 
selected wavelengths. The concentrations of the drug were determined using 
respective linear regression equations. 
3. MEthod VAlIdAtIon
3.1 Accuracy
accuracy of the methods was studied at three different levels i.e. 80%, 100% 
and 120% levels. To the pre-analyzed sample solution (9µg of eptifibatide), 
a known amount of stock standards solution of eptifibatide were at three 
different levels 80%, 100% and 120%. These solutions were re-analyzed by 
the proposed methods. 
3.2 Precision
For repeatability; six replicates of sample solution were scanned at concentration 
of 9 µg/ml. The experiments were performed at three different concentration 
levels (6, 9 and 12 µg/ml) and repeated three times in a day to determine intra-
day precision and on three different days to determine inter-day precision.
Figure 3: First order derivative uV- Spectrum of eptifibatide showing 










The sensitivity of the methods was assessed as limit of Detection (lOD) and 
limit of Quantification (lOQ). To determine lOD and lOQ, the concentration 
at the low end of the linear range of the calibration plot were analysed. lOD and 
lOQ were calculated using equation lOD = 3.3 × N/B and lOQ = 10 × N/B; 
Where, ‘N’ is the standard deviation of the peak areas of the drugs (n = 3), taken 
as a measure of noise, and ‘B’ is the slop of the corresponding calibration plot. 
3.4 Ruggedness
Ruggedness of the methods was performed by two different analysts at 
concentration level 9 µg/ml.
4. RESUltS And dIScUSSIon 
eptifibatide showed maximum absorption at 218.20 nm in distilled water and 
obeyed linearity in the concentration range of 3 -18 µg/ml at their respective 
Parameter Method-I Method-II
Wavelength(s) 218. 20 nm 220.20- 237.20 nm 
linearity [µg/ml] 3  - 18 3 - 18
linearity equation Y= 0.0473 X + 0.0389 Y= 0.1278 X + 0.0737
Slope ± SD 0.0473 ± 0.0005 0.1278 ± 0.0001
Intercept ± SD 0.0389 ± 0.0002 0.0737 ± 0.0004
Correlation Coefficient ± SD 0.999 ± 0.0004 0.999 ± 0.0002











[n= 6] % RSd
99.60 0.78 100.02 0.76






wavelengths in both the proposed methods. The optical characteristic and 
linearity data of both these methods are shown in Table 1. 
The amount of the eptibatide estimated in pharmaceutical formulation using 
both these methods is shown in Table 2. The amounts estimated were found to 
be in good agreement with good agreement with label claimed. These methods 
were validated for accuracy, precision and ruggedness as per ICh guidelines. 
The accuracy of the methods were assessed at three different levels i.e. 80 %, 
100 % and 120 % level and methods were found to be accurate as indicated by 
low values of % RSD. The precision of the methods were studied as repeatability, 
intra-day and inter-day precision and the % RSD values were found to be less 
than 2 indicates methods are precise. both methods are simple, accurate and rapid 
can suitably be used for determination of eptifibatide in Parenteral formulation. 
Summary of validation parameters is shown in Table 3. 
5. conclUSIon 
both these developed methods are simple, rapid and economical. accuracy 
and precision are found within acceptable range. These methods proved to be 
rugged and can be used for routine analysis of eptifibatide in bulk and in its 
parenteral formulation.
Parameter Method-I Method-II
% Recovery [n= 9] 100.22 99.02





Intra-day [n=3] 1.44 - 1.66 0.76 -1.55
Inter-day [n =3] 1.36 -1.92 1.36-1.63
Repeatability [n=6] 1.21 1.05
Ruggedness [% RSD]
analyst – I [n= 6] 0.82 1.08
analyst – II [n= 6] 0.66 1.07
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